Pfizer vows to fight Lipitor copies in Canada

Generic forms of Pfizer's (NYSE: PFE) blockbuster Lipitor cholesterol fighter began flooding into Canada on Wednesday, in a taste of what is to come for the $12 billion-a-year drug next year in the U.S. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.